<div id="readability-page-1"><div>By Adria Calatayud Shares in argenx fell after the pharmaceutical company said it would stop late-stage trials for an experimental drug to treat thyroid eye disease due to lack of efficacy. In European afternoon trading Monday, Brussels-listed shares in argenx were down 6.9% at 701.60 euros, but have risen 17% since the start of the year. The Amsterdam-based company said it would discontinue the trials for the drug, Vyvgart subcutaneous, as a treatment for adults with thyroid eye disease, an autoimmune disease that can lead to vision loss in severe cases, the company said. The decision followed a recommendation from an independent data-monitoring committee and was based on a review of data from a planned futility analysis after 24 weeks in the studies, argenx said. The analysis showed the studies didn't meet argenx's desired outcome, it said. The drug showed a favorable safety and tolerability profile, with no new safety signals identified, the company added. This marks a surprising failure for Vyvgart and removes what was likely to be a major catalyst for its shares next year, analysts at UBS wrote in a note to clients. Nevertheless, data from previous studies for argenx's other late-stage trials are more robust, the analysts said. Write to Adria Calatayud at adria.calatayud@wsj.com (END) Dow Jones Newswires12-15-25 0915ET</div></div>

ARGX

Argenx 的股價下跌了 6.9%，原因是該公司宣佈將停止其甲狀腺眼病藥物 Vyvgart 皮下注射的後期臨牀試驗，原因是缺乏療效。該決定是基於無效性分析的建議。儘管如此，該藥物顯示出良好的安全性。瑞銀分析師指出，這一失敗消除了明年股價的一個主要催化劑，但其他後期臨牀試驗仍然穩健

Argenx 公司在放棄眼病藥物試驗後，股價下跌